Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46.2 -0.4 (-0.86%) Market Cap: 4.31 Bil Enterprise Value: 3.76 Bil PE Ratio: 0 PB Ratio: 13.42 GF Score: 81/100

Ultragenyx Pharmaceutical Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 02:20PM GMT
Release Date Price: €59 (-2.48%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good morning, everyone. Thanks for joining us at the Bank of America Healthcare Conference. I'm Tazeen Ahmad, one of the senior biotech analysts here at the bank. It's my pleasure this morning to introduce our next presenting company, Ultragenyx. Speaking for Ultragenyx this morning is Chief Financial Officer, Shalini Sharp. Good morning, Shalini.

Shalini Sharp
Ultragenyx Pharmaceutical Inc. - CFO & Executive VP

Good morning, Tazeen. Thanks for having us.

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Of course, we look forward to spending the next 30 minutes with you. Maybe as a starter, can you give anyone on the line who may not be as familiar with RARE a brief highlight of the company's recent accomplishments? And then we can talk about some upcoming catalysts in a little bit more detail.

Shalini Sharp
Ultragenyx Pharmaceutical Inc. - CFO & Executive VP

Sounds great. So thank you, everyone,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot